Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.66
(
-1.98%
)
Bitcoin
74,261.61
(
0.43%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 29799

Wednesday, 06/07/2006 2:53:15 PM

Wednesday, June 07, 2006 2:53:15 PM

Post# of 257253
rkrw re HGSI – I’m not sure why you evaluate the Albuferon deal using a different yardstick than you use for the IDIX and ANDS deals by calling it a drug-delivery deal rather than simply a drug deal.

Albuferon is a new molecular entity. I think it’s fair to evaluate it straight up against the IDIX NM283 deal, which was closed at a similar stage of development.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now